
    
      Phase III, randomized, controlled, multicenter, open label, superiority, 1:1 allocation,
      blind assessment of clinical outcomes and intention-to-treat analysis clinical trial to
      determine whether increased doses of influenza vaccine in the hospital phase, when compared
      to usual dose vaccination (30 days hospital discharge), reduce the risk of major
      cardiovascular events (cardiovascular mortality, acute myocardial infarction and stroke) in
      patients with acute coronary syndrome.
    
  